Search Results - "Khaertynova, Ilsiyar M."
-
1
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
Published in Human vaccines & immunotherapeutics (31-12-2023)“…Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination…”
Get full text
Journal Article -
2
Long Term Immune Response Produced by the SputnikV Vaccine
Published in International journal of molecular sciences (18-10-2021)“…SputnikV is a vaccine against SARS-CoV-2 developed by the Gamaleya National Research Centre for Epidemiology and Microbiology. The vaccine has been shown to…”
Get full text
Journal Article -
3
Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients
Published in Frontiers in microbiology (18-04-2022)“…Identifying immunogenic targets of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to advance diagnostic and disease control…”
Get full text
Journal Article -
4
Characterization of the Puumala orthohantavirus Strains in the Northwestern Region of the Republic of Tatarstan in Relation to the Clinical Manifestations in Hemorrhagic Fever With Renal Syndrome Patients
Published in Frontiers in pharmacology (05-09-2019)“…Over 1,000 cases of hemorrhagic fever with renal syndrome (HFRS) were recorded in the Republic of Tatarstan (RT) in 2015. HFRS is a zoonotic disease caused by…”
Get full text
Journal Article -
5
Urinary Clusterin Is Upregulated in Nephropathia Epidemica
Published in Disease markers (01-01-2018)“…Kidney insufficiency is a hallmark of nephropathia epidemica (NE). Little is known about the mechanisms of the NE kidney pathology, with current knowledge…”
Get full text
Journal Article -
6
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
Published in Open forum infectious diseases (01-03-2022)“…Abstract Background Adults with certain medical and behavioral factors are at increased risk for pneumococcal disease (PD). Sequential vaccination with…”
Get full text
Journal Article -
7
Extraction and Serological Properties of Mycobacterium Cell Surface and Excreted Proteins
Published in BioNanoScience (01-03-2018)“…Modern medicine still faces the task of distinguishing active and latent tuberculosis cases at the early stage of the disease. Serological approaches have…”
Get full text
Journal Article -
8
Positive Correlation between Serum Tryglycerides and Pro-Inflammatory Cytokines in Hemorrhagic Fever with Renal Syndrome
Published in Blood (08-12-2017)“…Hemorrhagic fever with renal syndrome (HFRS) is endemic in the Republic of Tatarstan. Clinically, it is characterized by kidney insufficiency and hemorrhagic…”
Get full text
Journal Article -
9
1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors
Published in Open forum infectious diseases (04-12-2021)“…Abstract Background Risk factors (RFs) for pneumococcal disease (PD) in immunocompetent individuals include comorbidities, behavioral habits, or living in a…”
Get full text
Journal Article